Premium
Immune‐Related Adverse Events From Immune Checkpoint Inhibitors
Author(s) -
Marrone KA,
Ying W,
Naidoo J
Publication year - 2016
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.394
Subject(s) - adverse effect , immune system , immunotherapy , medicine , cancer immunotherapy , immune checkpoint , immunology , pharmacology
Immunotherapy for cancer treatment has come of age, specifically with the use of immune checkpoint antibodies directed against molecules such as CTLA‐4, PD‐1, and PD‐L1. Single‐agent and combinatorial approaches utilizing these agents and other immunotherapies that may enhance antitumor effects are under investigation. With increasing clinical use of these agents, an appreciation for their toxicities comes to the fore. Adverse events that occur as a result of the immunologic effects of these therapies are termed “immune‐related adverse events” (irAEs), and range in both frequency and severity in reported single‐agent and combination studies. Improvements in our understanding of how and why irAEs develop and how to effectively manage them are needed. Herein we provide a state‐of‐the‐art synopsis of the incidence, clinical features, mechanisms, and management of selected irAEs with immune checkpoint inhibitors currently in use.